Mayo Clinic's approach


Mayo Clinic has been studying the use of convalescent plasma for many years and has used the therapy for treating infectious diseases. Through clinical trials, researchers have collected data and developed lifesaving procedures.

Mayo Clinic joined with medical centers across the U.S. to collect plasma from people who have recovered from COVID-19 to be used for convalescent plasma therapy. Mayo Clinic coordinated this government-sponsored program.

Team approach

A team of Mayo doctors in many areas, including infectious diseases, laboratory medicine and pathology, blood collection and testing (transfusion medicine), pharmacy, virus studies (virology), and cardiovascular diseases, works together to study potential treatments for COVID-19 such as convalescent plasma therapy.


Mayo Clinic researchers are studying the virus that causes COVID-19 and how it affects the immune system. They're also studying drugs and treatments for COVID-19, including convalescent plasma.

Researchers are also working on on diagnostic and antibody tests, and are working to inform medical centers about ways to prevent and control infections. Researchers are active in clinical trials for COVID-19 and other infectious diseases.

April 28, 2021
  1. Convalescent plasma COVID-19: EUA letter of authorization. U.S. Food and Drug Administration. Accessed April 22, 2021.
  2. Joyner MJ, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: Initial three month experience. Preprint. medRxiv. 2020; doi:10.1101/2020.08.12.20169359.
  3. FDA issues emergency use authorization for convalescent plasma as potential promising COVID–19 treatment. U.S. Food and Drug Administration. Accessed Aug. 24, 2020.
  4. Host modifiers and immune-based therapy under evaluation for treatment of COVID-19. National Institutes of Health. Accessed May 8, 2020.
  5. Donate COVID-19 plasma. U.S. Food and Drug Administration. Accessed Aug. 24, 2020.
  6. Plasma donations from recovered COVID-19 patients. American Red Cross. Accessed May 8, 2020.
  7. Rajendran K, et al. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. Journal of Medical Virology. 2020; doi:10.1002/jmv.25961.
  8. Investigational COVID-19 convalescent plasma — Emergency INDs: Frequently asked questions. U.S. Food and Drug Administration. Accessed May 8, 2020.
  9. Expanded access to convalescent plasma for the treatment of patients with COVID-19. Accessed Aug. 24, 2020.
  10. Coronavirus disease 2019 (COVID-2019). Centers for Disease Control and Prevention. Accessed May 8, 2020.
  11. Kim AR. Coronavirus disease 2019 (COVID-19): Management in hospitalized adults. Accessed May 8, 2020.
  12. AskMayoExpert. COVID-19: Adult. Mayo Clinic; 2020.
  13. Joyner MJ (expert opinion). Mayo Clinic. May 8, 2020.
  14. Emergency use authorization. U.S. Food and Drug Administration. . Accessed April 22, 2021.
  15. Coronavirus disease 2019 (COVID-19) treatment guidelines: Convalescent plasma. National Institutes of Health. Accessed April 22, 2021.
  16. Klassen SA, et al. The effect of convalescent plasma therapy on COVID-19 patient mortality: Systematic review and meta-analysis. Mayo Clinic Proceedings. 2021; doi:10.1016/j.mayocp.2021.02.008.
  17. Joyner MJ, et al. Convalescent plasma antibody levels and risk of death from COVID-19. The New England Journal of Medicine. 2021; doi:10.1056/NEJMoa2031893.